Practical radiation oncology · 2026
Real-World Clinical Outcomes in Patients With Limited-Stage Small Cell Lung Cancer Who Received High-Dose Hyperfractionated Simultaneous Integrated Boost Radiation Therapy Versus Standard-Dose Radiation Therapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Jiayi, Zhang Jingwei, Chang Xiao, Yang Dan, Shan Jiahui, Jiang Leilei, Long Liuhua, Teng Yue, Dong Xin, Yu Rong, Yu Huiming, Zhao Jun, Ma Shaohua, Shi Anhui
Аннотация
PURPOSE: A phase 3 trial has shown that high-dose, accelerated, hyperfractionated, twice-daily thoracic radiation therapy (54 Gy in 30 fractions) is clinically effective for patients aged <70 years with limited-stage small cell lung cancer (LS-SCLC). This retrospective study compares the real-world effectiveness of high-dose hyperfractionated simultaneous integrated boost radiation therapy with standard-dose radiation therapy.
METHODS AND MATERIALS: This retrospective study was conducted at Peking University Cancer Hospital, including patients with histologically or cytologically confirmed LS-SCLC. All eligible patients received 4 courses of thoracic radiation therapy combined with concurrent chemotherapy (cisplatin or carboplatin and etoposide). Patients were categorized into 3 groups based on the radiation therapy dose: (1) the 54 Gy group (54 Gy in 30 fractions, twice daily); (2) the 45 Gy group (45 Gy in 30 fractions, twice daily); and (3) the 60 Gy group (60-70 Gy in 30-35 fractions, once daily). The primary endpoints were real-world progression-free survival and overall survival.
RESULTS: Between March 2010 and November 2024, a total of 353 patients were included in the study. The median follow-up was 54.9 months (range, 2.9-151.6 months). After applying inverse probability of treatment weighting (IPTW), the clinical features were well balanced between the groups. The median real-world progression-free survival was significantly better in the 54 Gy group (29.7 months [95% CI, 15.9-not reached]) compared with the 45 Gy group (15.0 months [95% CI, 11.8-30.4]; hazard ratio [HR], 1.23 [95% CI, 1.01-1.50]) and the 60 Gy group (13.5 months [95% CI, 11.4-15.9]; HR, 1.29 [95% CI, 1.09-1.54]) both before (P = .011) and after (P = .033) IPTW. The median overall survival was also significantly longer in the 54 Gy group (63.9 months [95% CI, 57.1-not reached]) compared with the 45 Gy group (42.9 months [95% CI, 32.3-70.8]; HR, 1.76 [95% CI, 1.19-2.61]) and the 60 Gy group (38.0 months [95% CI, 30.8-51.9]; HR, 1.60 [95% CI, 1.05-2.44]) both before (P = .015) and after (P = .006) IPTW. Treatment-related toxicities were similar across the 3 groups.
CONCLUSIONS: High-dose, accelerated, hyperfractionated, twice-daily thoracic radiation therapy (54 Gy) was well tolerated and effective in this large, real-world cohort study of patients with LS-SCLC compared with standard-dose (45 Gy twice daily and 60-70 Gy every day) radiation therapy.
METHODS AND MATERIALS: This retrospective study was conducted at Peking University Cancer Hospital, including patients with histologically or cytologically confirmed LS-SCLC. All eligible patients received 4 courses of thoracic radiation therapy combined with concurrent chemotherapy (cisplatin or carboplatin and etoposide). Patients were categorized into 3 groups based on the radiation therapy dose: (1) the 54 Gy group (54 Gy in 30 fractions, twice daily); (2) the 45 Gy group (45 Gy in 30 fractions, twice daily); and (3) the 60 Gy group (60-70 Gy in 30-35 fractions, once daily). The primary endpoints were real-world progression-free survival and overall survival.
RESULTS: Between March 2010 and November 2024, a total of 353 patients were included in the study. The median follow-up was 54.9 months (range, 2.9-151.6 months). After applying inverse probability of treatment weighting (IPTW), the clinical features were well balanced between the groups. The median real-world progression-free survival was significantly better in the 54 Gy group (29.7 months [95% CI, 15.9-not reached]) compared with the 45 Gy group (15.0 months [95% CI, 11.8-30.4]; hazard ratio [HR], 1.23 [95% CI, 1.01-1.50]) and the 60 Gy group (13.5 months [95% CI, 11.4-15.9]; HR, 1.29 [95% CI, 1.09-1.54]) both before (P = .011) and after (P = .033) IPTW. The median overall survival was also significantly longer in the 54 Gy group (63.9 months [95% CI, 57.1-not reached]) compared with the 45 Gy group (42.9 months [95% CI, 32.3-70.8]; HR, 1.76 [95% CI, 1.19-2.61]) and the 60 Gy group (38.0 months [95% CI, 30.8-51.9]; HR, 1.60 [95% CI, 1.05-2.44]) both before (P = .015) and after (P = .006) IPTW. Treatment-related toxicities were similar across the 3 groups.
CONCLUSIONS: High-dose, accelerated, hyperfractionated, twice-daily thoracic radiation therapy (54 Gy) was well tolerated and effective in this large, real-world cohort study of patients with LS-SCLC compared with standard-dose (45 Gy twice daily and 60-70 Gy every day) radiation therapy.